Skip to content
Corporate VCAllocates capital directlyActive · deal in last 18 monthsLAST VERIFIED Oct 2026 · 12 SOURCES

Angelini Ventures

Corporate venture capital arm of Angelini Industries (Angelini Holding S.p.A.)

Also known as Angelini Ventures S.p.A.

Rome-based corporate venture capital firm of Angelini Industries, founded in 2022 with €300M from the group; invests in biotech, medtech and digital health companies.

HEADQUARTERS
Rome, Italy
FOUNDED
—
AUM
—
OUTSIDE CAPITAL
—
TEAM LISTED
4 people

FOCUS

STAGES
Series ASeries BGrowth
SECTORS
Biotech & Life SciencesHealthTech
ASSET MIX
Venture capital
GEOGRAPHY
EuropeNorth America

WHAT IT IS

Corporate VC. A corporation investing from its own balance sheet, usually with strategic goals.

ABOUT

Angelini Ventures S.p.A. is the corporate venture capital firm of the Italian industrial group Angelini Industries, with its head office in Rome. It was founded in 2022 with €300 million from Angelini Industries; by December 2025 it had invested €125 million in 22 startups. In December 2025 it signed a €150 million co-investment agreement with the European Investment Bank, under which each party will invest €75 million over six years in seven to ten European biotechnology, medtech and digital health startups.

INVESTMENT THESIS

Biotechnology, medtech and digital health companies in Europe and North America.

PORTFOLIO (6)

  • RougeTx
    Biotech & Life Sciences · since 2026
  • Epicrispr Biotechnologies
    Biotech & Life Sciences · since 2026
  • MMI (Medical Microinstruments)
    HealthTech · since 2026
  • Handspring Health
    HealthTech · since 2026
  • Freya Biosciences
    Biotech & Life Sciences · since 2023
  • Argobio (venture studio, with Kurma Partners and Bpifrance)
    Biotech & Life Sciences

TEAM

  • Paolo Di Giorgio
    CEO · source
  • Tanja Dowe
    Managing Director · source
  • Regina Hodits
    Managing Director · source
  • Fabrizio Calisti
    Senior Medical Director · source

LINKS

FAQ

Angelini Ventures is a corporate venture arm based in Rome, Italy.

Yes. Angelini Ventures invests directly in private companies.

Angelini Ventures invests at Series A, Series B and Growth stages in Biotech & Life Sciences and HealthTech.

Key people at Angelini Ventures include Paolo Di Giorgio (CEO), Tanja Dowe (Managing Director), Regina Hodits (Managing Director) and Fabrizio Calisti (Senior Medical Director).

Angelini Ventures's investments include RougeTx, Epicrispr Biotechnologies, MMI (Medical Microinstruments), Handspring Health, Freya Biosciences and Argobio (venture studio, with Kurma Partners and Bpifrance).

The most recent publicly reported investment by Angelini Ventures is RougeTx ($58M Series A (co-led with BGV, the EIB co-investment facility Aurea and Kurma Partners)), announced in Oct 2026.